Age-groups | N | Prevalence rate (95% CI) | Awareness rate (95% CI) | Treated rate in diagnose (95% CI) | Control rate in treated (95% CI) | Overall Control rate (95% CI) |
---|---|---|---|---|---|---|
Whole participants | ||||||
18–44 | 1950 | 19.8(18.0,21.5) | 14.3(10.8,17.8) | 78.2(67.3,89.1) | 30.2(16.5,44.0) | 3.4(1.6,5.2) |
45–59 | 1210 | 46.0(43.2,48.8) | 50.7(46.6,54.9) | 90.1(86.6,93.6) | 40.6(34.5,46.6) | 18.5(15.3,21.8) |
60- | 1259 | 64.8(62.1,67.4) | 70.6(67.8,73.4) | 91.3(89.0,93.6) | 37.8(33.7,42.0) | 24.4(21.4,27.3) |
Total | 4419 | 39.8(38.3,41.2) | 51.9(49.6,54.3) | 90.1(88.2,92.1) | 38.3(35.0,41.6) | 17.9(16.1,19.7) |
Males | ||||||
18–44 | 978 | 29.8(26.9,32.6) | 11.0(7.4,14.6) | 78.1(63.8,92.5) | 36.0(17.2,54.8) | 3.1(1.1,5.1) |
45–59 | 600 | 53.0(49.0,57.0) | 48.7(43.3,54.2) | 91.0(86.5,95.5) | 38.3(30.3,46.3) | 17.0(12.9,21.1) |
60- | 602 | 67.3(63.5,71.0) | 72.8(68.5,77.2) | 89.5(86.0,93.0) | 37.1(31.3,43.0) | 24.2(20.0,28.4) |
Total | 2180 | 46.5(44.4,48.6) | 47.5(44.5,50.6) | 89.2(86.4,92.0) | 37.4(32.9,42.0) | 15.9(13.6,18.1) |
Females | ||||||
18–44 | 972 | 9.7(7.8,11.5) | 24.5(15.9,33.2) | 78.3(61.4,95.1) | 22.2(3.0,41.4) | 4.3(0.2,8.3) |
45–59 | 610 | 39.2(35.3,43.1) | 53.1(46.8,59.5) | 89.0(83.5,94.4) | 43.4(34.2,52.5) | 20.5(15.4,25.6) |
60- | 657 | 62.6(58.9,66.3) | 68.4(63.9,72.9) | 93.2(90.3,96.2) | 38.6(32.7,44.4) | 24.6(20.4,28.7) |
Total | 2239 | 33.2(31.3,35.2) | 57.9(54.4,61.5) | 91.2(88.5,93.9) | 39.2(34.4,44.0) | 20.7(17.8,23.6) |